Akeso’s ivonescimab, a PD-1/VEGF bispecific, met a key Phase 3 overall survival milestone in Harmoni-6, with an interim analysis presented at ASCO 2026. The data showed a statistically significant reduction in the risk of death versus a PD-1 inhibitor plus chemotherapy comparator in previously untreated advanced squamous non-small cell lung cancer. The readout is clinically consequential because VEGF blockade strategies have historically struggled to translate progression-free survival signals into overall survival gains in this disease setting. Akeso’s disclosure adds urgency to the competitive landscape, where multiple companies are already presenting and positioning bispecific and ADC strategies to move beyond checkpoint inhibitor backbones. For trial planners and payers, the immediate issue becomes how ivonescimab will be positioned versus established standards and which patient subsets may define uptake after mature endpoints.